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Abstract
Background: Evidence has emerged showing that elderly people and those with pre-existing chronic health
conditions may be at higher risk of developing severe health consequences from COVID-19. In Europe, this is of
particular relevance with ageing populations living with non-communicable diseases, multi-morbidity and frailty.
Published estimates of Years Lived with Disability (YLD) from the Global Burden of Disease (GBD) study help to
characterise the extent of these effects. Our aim was to identify the countries across Europe that have populations
at highest risk from COVID-19 by using estimates of population age structure and YLD for health conditions linked
to severe illness from COVID-19.
Methods: Population and YLD estimates from GBD 2017 were extracted for 45 countries in Europe. YLD was
restricted to a list of specific health conditions associated with being at risk of developing severe consequences
from COVID-19 based on guidance from the United Kingdom Government. This guidance also identified individuals
aged 70 years and above as being at higher risk of developing severe health consequences. Study outcomes were
defined as: (i) proportion of population aged 70 years and above; and (ii) rate of YLD for COVID-19 vulnerable
health conditions across all ages. Bivariate groupings were established for each outcome and combined to establish
overall population-level vulnerability.
Results: Countries with the highest proportions of elderly residents were Italy, Greece, Germany, Portugal and
Finland. When assessments of population-level YLD rates for COVID-19 vulnerable health conditions were made, the
highest rates were observed for Bulgaria, Czechia, Croatia, Hungary and Bosnia and Herzegovina. A bivariate analysis
indicated that the countries at high-risk across both measures of vulnerability were: Bulgaria; Portugal; Latvia;
Lithuania; Greece; Germany; Estonia; and Sweden.
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Conclusion: Routine estimates of population structures and non-fatal burden of disease measures can be usefully
combined to create composite indicators of vulnerability for rapid assessments, in this case to severe health
consequences from COVID-19. Countries with available results for sub-national regions within their country, or
national burden of disease studies that also use sub-national levels for burden quantifications, should consider
using non-fatal burden of disease estimates to estimate geographical vulnerability to COVID-19.
Keywords: COVID-19, Coronavirus, Burden of disease, DALY, YLD, Summary measures of population health, GBD,
Vulnerability, European burden of disease network
Background
In burden of disease studies, estimates of disability-
adjusted life years (DALYs) are commonly used to assess
the leading causes of burden amongst populations [1].
DALYs are composed of estimates of population health
loss due to living with the consequences of morbidity
and premature mortality. Years Lived with Disability
(YLD) capture the morbidity (both the prevalence and
severity of the disease) component of DALYs by estimat-
ing the number of years lost due to conditions diminish-
ing the overall health status, and are a useful indicator
to assess how impaired populations are due to living
with the consequences of disease and injury [2].
Internationally, countries have reacted to the COVID-19
outbreak by introducing key public health non-
pharmaceutical interventions (otherwise known as phys-
ical, or social, distancing) to protect vulnerable population
groups [3]. Evidence has emerged to show that elderly
people and those with pre-existing multi-morbid condi-
tions may be at higher risk of developing severe health
consequences from COVID-19 [4]. In Europe, 31% of the
population are estimated to have a condition that is on
the Government of the United Kingdom’s (UK) list of
conditions at increased risk of severe health consequences
from COVID-19 disease [5]. There is currently a disparity
of comparable information across countries to objectively
assess country-level vulnerability to COVID-19. However,
there is a wealth of data on population structure, health
status and causes of health loss in countries, which can be
obtained from the Global Burden of Disease (GBD) study
[6]. These data can be used to approximate how vulner-
able populations are, particularly by focusing on the popu-
lation share of elderly residents and the YLD for health
conditions that have been identified as potentially linked
to severe illness from COVID-19. This is of particular
relevance for European countries, as increases in lifespan
have resulted in increasingly ageing populations living
with effects of non-communicable diseases, multi-
morbidity and frailty [7].
The aim of this study was to identify the countries
across Europe that have populations at highest risk for
severe disease progression after COVID-19 infection by
using estimates of population structure and YLD for
health conditions linked to severe illness from COVID-
19. This study was carried out using data from GBD
2017 for the reference year 2017, considering two mea-
sures of vulnerability: (i) rate of elderly population; and
(ii) rate of YLD for health conditions identified at risk of
severe health consequences from COVID-19.
Methods
Data
The GBD Results Tool [8] was used to extract Years
Lived with Disability (YLD) estimates for both sexes,
age-groups (all ages; 70 years and above; and 80 years
and above) and GBD 2017 level 3 cause [9] for each
country defined as residing in Central, Eastern and
Western Europe (N = 45 countries). Estimates were con-
sidered for the constituent nations of the United King-
dom (UK): England; Northern Ireland; Scotland; and
Wales, rather than the UK as a whole. In this study,
hereafter, the elderly population denotes the age-group
70 years and above.
Data were retained for specific causes based on guid-
ance from the UK Government (as at 30th March 2020)
on those health conditions that indicated a risk of severe
health consequences from COVID-19 [10]. Two groups
were defined: individuals aged 70 years and above, and
those under 70 years that have one or more pre-existing
underlying health condition. The guidance provided by
the UK Government is outlined in the Supplementary
Appendix and the list of pre-existing conditions were
mapped to the GBD 2017 cause list (Table 1).
Some emerging evidence has considered obesity and
hypertension as independent risk factors for severe
health consequences from COVID-19 [11, 12]. How-
ever, we do not consider them separately in this study
as the vast majority of disease outcomes associated with
these risk factors are included in the mapping to the
GBD cause list (Table 1). For hypertension, all disease
outcomes linked to the high systolic blood pressure risk
factor are included (cardiovascular diseases and chronic
kidney disease in Table 1). In addition, GBD include
separate estimates for hypertensive disease and these
are included within cardiovascular diseases. The disease
outcomes associated with obesity are also all covered in
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the mapping to the GBD cause list with the exception
of Gout. Gout accounted for only 0.2% (95% uncer-
tainty interval: 0.15–0.25%) of total YLD in GBD Euro-
pean Region in 2017 [8].
A permalink to the GBD Results Tool [8] query that
were used to generate the data used in this study are
outlined in the Data Availability section. Additionally,
data on the total 2017 resident populations and
population aged 70 years and above for each country
were sourced from the Global Health Data Exchange
(GHDx) [13]. These population denominators were used
in the production of GBD 2017 estimates.
Analyses
Descriptive summaries were calculated for the propor-
tion of elderly population, and YLD for COVID-19 vul-
nerable health conditions were described using crude
rates per 100,000 population. The numerators for the
population proportion calculations were based on elderly
populations, whereas the YLD rate calculation numera-
tors were based on population totals. Denominators
were based on the all ages population data sourced from
GHDx [13].
Each measure was divided into tertiles (three binned
categories: low; mid; and high). These categories were
calculated to determine three equal size groups of vul-
nerability. Bivariate groupings were established by con-
sidering the overlapping of the measures and were
depicted in a scatter plot to identify groups of countries,
both in terms of the proportion of elderly population
and the rate of YLD for conditions associated with worse
COVID-19 prognosis. Spearman’s rank correlation coef-
ficient (ρ) was used to describe the correlation between
the percentage of elderly population and the rate of YLD
for COVID-19 vulnerable health conditions.
Results
Proportions of elderly population by country
The five countries with the highest proportions of eld-
erly residents (aged 70 years and above) were: Italy
(16.4%); Greece (16.2%); Germany (15.4%); Portugal
(15.3%); and Finland (14.7%) (Table 2). Conversely, the
countries with the lowest proportions of elderly popula-
tion were Israel (7.7%); Moldova (8.2%); Russian Feder-
ation (8.8%); Macedonia (8.8%); and Albania (9.1%). The
ratio of the country with the highest (Italy) and lowest
(Israel) proportion of elderly residents was 2.14, indicat-
ing over a two-fold difference between the countries.
When looking at stratified differences within the eld-
erly age-group, the five countries with the highest per-
centage of population aged 80 years and above were:
France (44.5%); Spain (44.4%); Greece (43.2%); Belgium
(42.2%) and Italy (41.7%). The five countries with the
lowest percentage of population aged 80 years and above
were: Albania (30.8%); Bosnia and Herzegovina (31.4%);
Czechia (31.5%); Macedonia (32.4%); and Montenegro
(32.5%). Between the country with the highest (France)
percentage of population aged 80 years and above and
lowest (Albania), there was an absolute difference of
13.7%.
Table 1 Mapping of UK Government guidance on pre-existing
medical conditions at risk of severe illness from COVID-19 to the
GBD 2017 cause list
Pre-existing health condition(s) GBD mapped cause(s)
All health conditions All-causes




Interstitial lung disease and
pulmonary sarcoidosis
Other chronic respiratory diseases
Chronic heart disease Cardiovascular diseases (chronic and
acute)
Chronic kidney disease Chronic kidney disease
Chronic liver disease Cirrhosis and other chronic liver
diseases













Cancers of the blood or bone
marrow
Seriously overweight Covered in mapping for chronic
respiratory diseases, cardiovascular
diseases, chronic kidney disease,
cirrhosis and chronic liver diseases,
and diabetes
Severe chest conditions such as
cystic fibrosis or severe asthma
Covered in mapping for chronic
respiratory diseases
Organ transplant and remain on
ongoing immunosuppression
medication
Covered in mapping for chronic
kidney disease
Severe disease of body systems Covered in mapping from all pre-
existing health conditions
Those who are pregnant Not covered
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Rate of YLD for COVID-19 vulnerable health conditions
When the rate of YLD for health conditions associated
with higher COVID-19 vulnerability was assessed for all
ages, the five countries with the highest rates per 100,
000 population were: Bulgaria (3760); Czechia (3690);
Croatia (3651), Hungary (3613); and Bosnia and
Herzegovina (3553) (Table 2). The five countries with
the lowest rates were: Israel (1870); Cyprus (2272);
Moldova (2448); Albania (2460); and France (2505).
There was a rate ratio of 2.01 between the country with
the highest rate (Bulgaria) and the country with the low-
est rate (Israel).
Table 2 Summary of percentage of elderly population and YLD rates for COVID-19 vulnerable health conditions, by country, 2017
Country order is based on the descending proportion of elderly residents. Cells shaded in orange represent the highest values within each metric, with cells
shaded in green representing the lowest value
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Insights into rates of YLD for health conditions indi-
cating higher COVID-19 vulnerability for those under
70 years and elderly residents were that there were four
countries that were common amongst the leading five
countries in both age-groups. These countries were:
Czechia, Croatia, Hungary and Bosnia and Herzegovina.
Of the five countries with the lowest rates in the under
70 years and elderly age-groups, there were three coun-
tries that were common: Israel, France and Spain.
Summary of combined vulnerability
There was a moderate association (ρ = 0.54) between the
percentage of elderly population and the rate of YLD for
COVID-19 vulnerable health conditions. A bivariate ana-
lysis indicated that the countries which had high propor-
tions of elderly population and high rates of YLD for
COVID-19 vulnerable health conditions were: Bulgaria;
Portugal; Latvia; Lithuania; Greece; Germany; Estonia;
and Sweden. Conversely, the countries with the lowest
proportions of elderly population and lowest rates of
YLD for COVID-19 vulnerable health conditions were:
Israel; Cyprus; Moldova; Albania; Andorra; Ireland; Rus-
sian Federation; Iceland; and Belarus. Bosnia and
Herzegovina had a high rate of YLD for COVID-19 vul-
nerable health conditions, but a relatively low proportion
of elderly population. On the other hand, Spain, France
and Austria all had high proportions of elderly popula-
tion but a relatively low rate of YLD for COVID-19 vul-
nerable health conditions (Fig. 1).
Discussion
Summary of findings
This study set out to establish which countries across
Europe had populations that were most likely to be vul-
nerable to severe health consequences as a result of
COVID-19 infection. This assessment was made using
data on population age structure, and data on YLD for
health conditions identified as increasing the risk of
COVID-19 severity, the latter illustrating the extent to
which populations are vulnerable through living with ill-
health due to causes of disease.
Estimates of vulnerability to COVID-19 using elderly
population share indicated that the countries with the
highest proportions of elderly residents were Italy,
Greece, Germany, Portugal and Finland. When assess-
ments of population-level YLD rates for COVID-19
vulnerable health conditions were made the highest rates
were observed for Bulgaria, Czechia, Croatia, Hungary
and Bosnia and Herzegovina. Our bivariate analysis indi-
cated that the countries which had high rates across
both measures of vulnerability were: Bulgaria; Portugal;
Latvia; Lithuania; Greece; Germany; Estonia; and
Sweden.
Whilst these findings indicate population-level vul-
nerability due to health loss suffered, they do not take
into account other important factors such as country
and sub-national responses to the COVID-19 out-
break through public health non-pharmaceutical inter-
ventions. Neither do they take into account factors
such as: population density, the capacity or ease of
access to health and social care services and the dis-
ruption to existing services due to the COVID-19 cri-
sis, all of which will have a significant impact on the
extent to which vulnerable populations are adequately
protected from harm. This may partly explain why
countries identified in this analysis with high and low
vulnerability to severe health consequences from
COVID-19 do not always correspond with those
countries in Europe with the highest and lowest case
fatality ratios due to COVID-19 [14]. For example,
within the Baltic states Latvia and Estonia have high
vulnerability as measured on both indicators. How-
ever, Latvia responded to the crisis quickly by closing
their borders and implementing restrictive measures
much faster than Estonia, and case fatality rates are
higher in Estonia [14–16]. This example highlights
that a number of additional factors could contribute
to differences between vulnerability and extent of ad-
verse consequences, including: care identification and
under-reporting, the speed at which countries intro-
duced restrictive measures, and restrictions on air
travel. The use of summary health indicator such as
YLD to identify severe health consequences from
COVID-19 infections should be regarded as just one
of the elements that need to be taken into account in
a complete risk assessment of vulnerability.
Strengths and limitations
The study was carried out using estimates from GBD
2017, which is a widely used and well-established mech-
anism that has methodological consistency when produ-
cing estimates for individual countries [6]. The use of
GBD 2017 is advantageous as estimates are publically ac-
cessible, which allows for the rapid assessments of im-
pact in response to public health emergency scenarios,
such as the COVID-19 outbreak. Our findings are com-
parable on a like-for-like basis across countries. How-
ever, data sources that are fed into the modelling
process for country-level estimates can vary based on lo-
cation, therefore there is a risk that some of the differ-
ences which we observe may be attributed to the use, or
omission, of high quality data sources [17]. We have
opted not to include estimates of uncertainty in our esti-
mates. Uncertainty intervals in the GBD study can often
be wide, representing large degrees of uncertainty, so
users of these results must bear in mind that these find-
ings relate to the best available point-estimate. To retain
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consistency with estimates of YLD from GBD 2017, data
on population size and structure was obtained from
GHDx [13] which may differ from nationally produced
estimates.
Previous research has suggested that the assumption
of fixed severity distributions across countries may be
unreasonable [18]. In our study of COVID-19 related
vulnerable conditions, we did not include some of the
leading causes of YLD, such as major depressive disor-
ders and substance use disorders, which are thought to
be the most likely to be affected by this assumption.
Thus, our COVID-19 vulnerable conditions analysis may
be less affected by this assumption [19]. Additionally,
our study has assumed that the extent of vulnerability to
COVID-19 can be determined by disability weights. For
example, on average a greater weight would be given to
those suffering from chronic obstructive pulmonary dis-
ease than to ischaemic heart disease [20]. This assump-
tion may be problematic if the risk of COVID-19
associated with each health condition is not
Fig. 1 Scatter plot of percentage of elderly population versus rate of YLD for COVID-19 vulnerable health conditions for European countries. Rates
described are crude rates per 100,000 population. White vertical and horizontal gridlines indicate the tertile dividing lines for the measures:
percentage of elderly population; and rate of YLD for COVID-19 vulnerable health conditions, respectively
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representative of relative differences in disability weight
between causes. Also, particular combinations of disease
may result in higher risks of consequences of COVID-
19, while all combinations are in this approach assumed
to have a similar effect.
We have used YLD as a proxy for the severity of
the selected vulnerable health conditions as YLD in-
cludes a weighting of the severity of diseases stages
i.e. a weighted prevalence. We have chosen to ex-
plore the aim of the YLD summary measure to com-
bine all conditions, rather than examine the impact
of individual causes. We acknowledge that using dis-
ease prevalence data from GHDx could add further
insight into quantifying the disease specific implica-
tions of severe health consequences from COVID-19.
However, since prevalence gives equal weighting to
each condition, we did not consider prevalence as
useful for summary analyses as YLD which allows a
weighted sum of prevalence of different diseases.
Further analysis has previously been carried out else-
where to explore using prevalence to quantify the
risk for severe health consequences from COVID-19
infection to enhance assessment of a health systems
vulnerability to COVID-19 [5].
Implications for policy and research
Our findings have important implications for decision-
making and for future research. In our assessment of
vulnerability, we have highlighted the countries in Eur-
ope with populations that are elderly, and vulnerable as
a result of reduced health due to certain health condi-
tions. From a decision-making perspective, this effect-
ively communicates how locations can be assessed on a
relative scale of risk of severe illness due to COVID-19.
Although, at time of this publication, many countries
have now employed public health non-pharmaceutical
interventions for over two months, there are still many
uncertainties about the further evolution of the pan-
demic and the virus itself. Therefore, until an effective
vaccination or treatment is available, our findings high-
light which countries have populations that are at high-
est risk and therefore should be prioritising the shielding
of vulnerable individuals. Doing so can alleviate the ex-
tent to which essential healthcare services are over-
whelmed, which will also contribute to curtailing the
indirect impact of COVID-19. Still, our results should
not be used as rationale for countries to justify a relaxing
of existing non-pharmaceutical interventions. The coun-
tries we identified as having indicators of low vulnerabil-
ity should not be complacent, as doing so would have
severe adverse consequences. Our findings also have im-
portant implications if there are positive breakthroughs
in the development of a vaccine that is both safe and
effective, as they highlight which countries may benefit
from it the most.
As research begins to focus on the evaluation of the im-
pact of public health non-pharmaceutical interventions, an
important aspect will be to establish baseline measures of
risk to severe illness of COVID-19. Our findings provide
an opportunity for this, particularly when assessing the
factors for success of these interventions in populations
that were facing similar levels of population vulnerability.
Conclusion
Our findings have highlighted that routine data on popula-
tion structure can be usefully extended by using estimates
of YLD to consider how populations are impaired by living
with the consequences of ill-health due to causes of disease
and injury. Countries with available estimates for sub-
national regions within their country, or national burden of
disease studies that also estimate at sub-national levels
should consider using non-fatal burden of disease estimates
to estimate geographical vulnerability to COVID-19.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13690-020-00433-y.
Additional file 1. Guidance on social distancing from the United
Kingdom Government.
Abbreviations
COVID-19: Coronavirus Disease 2019; DALYs: Disability-Adjusted Life Years;
GBD: Global Burden of Disease; GHDx: Global Health Data Exchange;
UK: United Kingdom; YLD: Years Lived with Disability
Acknowledgements
We would like to acknowledge the GBD 2017 study investigators and
collaborators, as without this study and their resulting estimates of
population and YLD our study would not have been possible. We would
also like to thank COST (European Cooperation in Science and Technology,
https://www.cost.eu), as this study was conducted within the framework of
COST Action CA18218 (European Burden of Disease Network).
Authors’ contributions
GW and IG generated the initial idea for the study. GW carried out all
analyses and visualisation of the results. GW drafted the manuscript with
assistance from IG. IG coordinated and made edits to the manuscript based
on responses from co-authors with assistance from GW. All other authors
provided critical input into the interpretation of the results, revisions to the
manuscript and approved the final draft.
Funding
This research received no specific grant from any funding agency in the
public, commercial or not-for-profit sectors. Journal open access publications
fees upon acceptance of this article in a peer-reviewed journal will be reim-
bursed under the COST action CA18218 (European Burden of Disease
Network).
Availability of data and materials
The datasets used in this research study are all publically available. The
permalink to data query used to obtain estimates of YLD is: http://ghdx.
healthdata.org/gbd-results-tool?params=gbd-api-2017-permalink/376
d9a9ad8401f49f104650fab0b9305.
Wyper et al. Archives of Public Health           (2020) 78:47 Page 7 of 8





All other authors declare that they have no competing interests.
Author details
1Place and Wellbeing Directorate, Public Health Scotland, Glasgow, Scotland,
UK. 2Food and Nutrition Department, National Institute of Health Dr. Ricardo
Jorge, Lisbon, Portugal. 3Department of Anatomy, Faculty of Medicine and
Surgery, University of Malta, Msida, Malta. 4Department of Epidemiology and
Public Health, Sciensano, Brussels, Belgium. 5Department of Veterinary Public
Health and Food Safety, Ghent University, Merelbeke, Belgium. 6Data Driven
Innovation Directorate, Public Health Scotland, Edinburgh, Scotland, UK.
7Department of Public Health, Erasmus MC University Medical Center,
Rotterdam, The Netherlands. 8National Institute for Public Health and the
Environment (RIVM), Bilthoven, The Netherlands. 9National Institute for Health
Development, Tallinn, Estonia. 10National Institute of Public Health, Ljubljana,
Slovenia. 11Department of Epidemiology and Health Monitoring, Robert Koch
Institute, Berlin, Germany. 12Department of Public Health, Institute for Global
Health and Epidemiology, Faculty of Health Sciences and Social Work, Trnava
University, Trnava, Slovakia. 13Faculty of Medicine University of Belgrade,
Belgrade, Serbia. 14MRC Clinical Trials and Methodology Unit, University
College London, London, UK. 15Unit of Noncommunicable Diseases,
Department of Public Health, Institute of Tropical Medicine, Antwerp,
Belgium. 16National Food Institute, Technical University of Denmark, Lyngby,
Denmark. 17Exposure Assessment and Environmental Health Indicators,
German Environment Agency, Berlin, Germany. 18MEDCIDS, Department of
Community Medicine, Information and Health Decision Sciences, Faculty of
Medicine, University of Porto, Porto, Portugal. 19CINTESIS, Centre for Health
Technology and Services Research, Porto, Portugal. 20Public Health Unit,
ACES Grande Porto VIII - Espinho/Gaia, ARS Norte, Porto, Portugal.
Received: 4 May 2020 Accepted: 19 May 2020
References
1. Murray CJL, Lopez AD. The global burden of disease: a comprehensive
assessment of mortality and disability from diseases, injuries and risk factors
in 1990 and projected to 2020. Cambridge: Harvard University Press on
behalf of the World Health Organization and the World Bank; 1996.
2. Klijs B, Nusselder WJ, Looman CW, Mackenbach JP. Contribution of chronic
disease to the burden of disability. PLoS One. 2011;6(9):e25325 https://doi.
org/10.1371/journal.pone.0025325.
3. Ebrahim SH, Ahmed QA, Gozzer E, Schlagenhauf P, Memish ZA. Covid-19
and community mitigation strategies in a pandemic. BMJ. 2020;368:m1066
https://doi.org/10.1136/bmj.m1066.
4. Matsushita K, Ding N, Kou M, Hu X, Chen M, Gao Y, et al. The relationship of
COVID-19 severity with cardiovascular disease and its traditional risk factors:
A systematic review and meta-analysis. medRxiv. 2020:20054155 https://doi.
org/10.1101/2020.04.05.20054155.
5. Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW et al. How
many are at increased risk of severe COVID-19 disease? Rapid global,
regional and national estimates for 2020. https://cmmid.github.io/topics/
covid19/Global_risk_factors.html.
6. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators.
Global, regional, and national incidence, prevalence, and years lived with
disability for 354 diseases and injuries for 195 countries and territories,
1990–2017: a systematic analysis for the Global Burden of Disease Study
2017. Lancet. 2018;392(10159):1789–858.
7. Brown GC. Living too long: the current focus of medical research on
increasing the quantity, rather than the quality, of life is damaging our
health and harming the economy. EMBO Rep. 2015;16(2):137–41.
8. Institute for Health Metrics and Evaluation. GBD Results Tool. Seattle:
University of Washington; 2018. http://ghdx.healthdata.org/gbd-results-tool
Accessed 10 Apr 2020.
9. Institute for Health Metrics and Evaluation. GBD 2017 causes of disease and
injuries. Seattle: University of Washington; 2018. http://www.healthdata.org/
sites/default/files/files/Projects/GBD/GBD_2017_heirarchies.zip Accessed 10
Apr 2020.
10. Public Health England. Guidance on social distancing for everyone in the
UK. United Kingdom Government. https://www.gov.uk/government/
publications/covid-19-guidance-on-social-distancing-and-for-vulnerable-
people/guidance-on-social-distancing-for-everyone-in-the-uk-and-
protecting-older-people-and-vulnerable-adults. Accessed 10 Apr 2020.
11. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al.
Obesity in patients younger than 60 years is a risk factor for Covid-19
hospital admission. Clin Infect Dis. 2020:ciaa415 https://doi.org/10.1093/cid/
ciaa415.
12. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes
mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;
8(4):e21 https://doi.org/10.1016/S2213-2600(20)30116-8.
13. Institute for Health Metrics and Evaluation. Global Health Data Exchange
(GHDx). Seattle: University of Washington; 2020. http://ghdx.healthdata.org/
Accessed 10 Apr 2020.
14. European Centre for Disease Prevention and Control. Data on the
geographic distribution of COVID-19 cases worldwide: European Union,
2020. https://www.ecdc.europa.eu/en/publications-data/download-todays-
data-geographic-distribution-covid-19-cases-worldwide/. Accessed 28 Apr
2020.
15. State Chancellery of the Republic of Latvia. Press releases. https://mk.gov.lv/
en/aktualitates/regarding-declation-emergency-situation. Accessed 28 Apr
2020.
16. Republic of Estonia Government. The government declared an emergency
situation in Estonia until 1 May. https://www.valitsus.ee/en/news/
government-declared-emergency-situation-estonia-until-1-may. Accessed 28
Apr 2020.
17. Steel N, Ford JA, Newton JN, Davis ACJ, Vos T, Naghavi M, et al. Changes in
health in the countries of the UK and 150 English local authority areas
1990–2016: a systematic analysis for the global burden of disease study
2016. Lancet. 2018;392(10158):1647–61 https://doi.org/10.1016/S0140-
6736(18)32207-4.
18. Wyper GMA, Grant I, Fletcher E, McCartney G, Stockton DL. The impact of
worldwide, national and sub-national severity distributions in burden of
disease studies: a case study of cancers in Scotland. PLoS One. 2019;14(8):
e0221026 https://doi.org/10.1371/journal.pone.0221026.
19. Wyper GMA, Grant I, Fletcher E, Chalmers N, McCartney G, Stockton DL.
Prioritising the development of severity distributions in burden of disease
studies for countries in the European region. Arch Public Health. 2020;78(3)
https://doi.org/10.1186/s13690-019-0385-6.
20. Global Burden of Disease Collaborative Network. Global Burden of Disease
Study 2016 (GBD 2016) Disability Weights. Seattle: United States: Institute for
Health Metrics and Evaluation (IHME); 2017.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Wyper et al. Archives of Public Health           (2020) 78:47 Page 8 of 8
